Abstract: A gas sensor includes: a gas-sensitive body layer disposed above a substrate and including a metal oxide layer; a first electrode on the gas-sensitive body layer; and a second electrode on the gas-sensitive body layer, being apart from the first electrode by a gap. The gas-sensitive body layer has a resistance change characteristic that reversibly transitions to a high-resistance state and a low-resistance state on basis of a voltage applied across the first electrode and the second electrode. At least a part of the gas-sensitive body layer is exposed to the gap. The gas-sensitive body layer has a resistance that decreases when gas containing a hydrogen atom is in contact with the second electrode.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: Provided is an inkjet active-energy-ray-curable composition including a bisphenol-type methacrylate, a low-viscosity monomer, and an inorganic filler.

Abstract: A culture apparatus includes a culture vessel including an internal space containing a culture solution in which a culture target is suspended, a gas supply apparatus supplying a single gas or a mixed gas to the internal space of the culture vessel, and an agitation apparatus agitating the culture solution by changing position and posture of the culture vessel. The agitation apparatus changes the position and posture of the culture vessel to circulate the culture solution in the internal space of the culture vessel so that a bottom surface of the internal space of the culture vessel is partially revealed and that the revealed portion transitions in a circulating direction R.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La—(CH2)n2—C(?O)—wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: A three-dimensional object producing method for producing a three-dimensional object using a curable composition A and a curable composition B, and using a curable composition C is provided. The method includes discharging either or both of the curable compositions A and B by an inkjet method and curing either or both of them, to produce a base cured product, and discharging the curable composition C containing a coloring material by an inkjet method and curing the curable composition C, to produce a cured product C. A deposited region C formed by deposition of the curable composition C discharged is smaller than a base deposited region formed by deposition of the curable compositions A and B discharged. An absolute value of a total light transmittance difference between a cured product A of the curable composition A and a cured product B of the curable composition B is 10% or greater.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position

Abstract: A curable composition containing a radical-polymerizable monomer and a hard solid component having a volume average particle diameter of 10 nm or greater and 1,000 nm or less is provided. The content of the hard solid component is 3% by volume or greater and 40% by volume or less. The difference (n1?n2) between the refractive index (n1) of a cured product of any other component than the hard solid component and the refractive index (n2) of the hard solid component is 0.04 or greater.

Abstract: A curable composition is provided. The curable composition contains a multifunctional urethane (meth)acrylate monomer (component 1), a (meth)acrylate monomer (component 2), and an inorganic filler (component 3). A mass content ratio (component 1:component 2) of the component 1 to the component 2 is from 65:35 through 40:60.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LF-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: Provided is a three-dimensional object producing method that includes applying an object forming liquid to powder including a base material and an organic material to form a solidified product, and removing the powder deposited on the solidified product from the solidified product using a powder removal liquid including an organic solvent. The following formulae are satisfied RED of non-forming part<1.20 and RED of forming part>0.55. The forming part is a portion of the powder to which the object forming liquid is applied and RED of the forming part is a distance between HSP of the forming part and HSP of the organic solvent. The non-forming part is a portion of the powder to which the object forming liquid is not applied and RED of the non-forming part is a distance between HSP of the non-forming part and HSP of the organic solvent.

Abstract: Provided is an inkjet active-energy-ray-curable composition including a bisphenol-type methacrylate, a low-viscosity monomer, and an inorganic filler.

Abstract: A cell suspension treatment apparatus has a circulation circuit and a filling liquid supply source that supplies a filling liquid to the circulation circuit. The circulation circuit includes a hollow fiber membrane filter, a reservoir, a pump that is provided on a downstream side of the reservoir and on an upstream side of the hollow fiber membrane filter, and a valve that is provided on the downstream side of the reservoir and on an upstream side of the pump. The filling liquid supply source is connected to a portion of the circulation circuit between the first valve and the pump. After the concentrated cell suspension is stored in the reservoir, in a state where the valve is closed and the pump is driven, the filling liquid supply source starts supplying the filling liquid to the circulation circuit to push the cell suspension, which remains in a portion of the circulation circuit from the pump to the inlet port of the reservoir, to flow toward the reservoir by the filling liquid.

Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the formula: L1-L2-LP-NH—(CH2)n1-La-Lb-Lc or -L1-L2-LP- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the terminal Lc or LP with the nitrogen atom of the amino group at position 1 as the connecting position.

Abstract: Provided is an active-energy-ray-curable liquid composition containing a monomer (A) having a hydrogen-bonding capacity and a solvent (B) having a hydrogen-bonding capacity, wherein the active-energy-ray-curable liquid composition satisfies conditions below, <Conditions> a cured product obtained by irradiating the active-energy-ray-curable liquid composition with 500 mJ/cm2 of an active energy ray is a solid having a compressive stress of 2.0 kPa or greater when compressed by 1% at 25 degrees C., and the cured product has a water decaying property.

Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

Abstract: An information processing apparatus and an information processing program can generate setting information to be set in devices even in an off-line state are provided. An information processing apparatus 10 according to the present invention includes: a storage 11 that stores setting information for each of setting items relating to a device connected to a communication network N; a display part 12 that displays a setting screen to which the setting information is input on a display 20; and a controller 13 that stores the setting information input to the setting screen in the storage. The setting screen includes: a first setting screen to which the setting information for each of the setting items relating to a first device in an on-line state of being connected to the communication network N is input; and a second setting screen to which the setting information for each of the setting items relating to a second device in an off-line state of being not connected to the communication network N is input.